You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePaclitaxel
Accession NumberDB01229  (APRD00259, DB05261, DB05927)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionPaclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]
Structure
Thumb
Synonyms
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Paclitaxel
Taxol
Taxol A
External Identifiers
  • ABI-007
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbraxaneInjection, powder, for suspension5 mg/mlIntravenousCelgene Europe Ltd  2008-01-11Not applicableEu
AbraxaneInjection, powder, for suspension5 mg/mlIntravenousCelgene Europe Ltd  2008-01-11Not applicableEu
AbraxaneInjection, powder, lyophilized, for suspension100 mg/20mLIntravenousAbraxis Bio Science, Llc2005-02-10Not applicableUs
Abraxane for Injectable SuspensionPowder, for suspension100 mgIntravenousCelgene Inc2006-08-31Not applicableCanada
Aj-paclitaxelSolution6 mgIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
PaclitaxelLiquid6 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
Paclitaxel for InjectionSolution6 mgIntravenousBiolyse Pharma Corporation2001-10-31Not applicableCanada
Paclitaxel for InjectionSolution6 mgIntravenousHospira Healthcare Corporation2007-12-17Not applicableCanada
Paclitaxel for InjectionSolution6 mgIntravenousTeva Canada LimitedNot applicableNot applicableCanada
Paclitaxel for Injection USPSolution6 mgIntravenousSterimax Inc2011-02-22Not applicableCanada
Paclitaxel InjectionLiquid6 mgIntravenousImmunex Corporation1997-10-242005-12-06Canada
Paclitaxel InjectionLiquid6 mgIntravenousDraxis Health Inc.Not applicableNot applicableCanada
Paclitaxel Injection USPSolution6 mgIntravenousSandoz Canada Incorporated2015-03-31Not applicableCanada
Paclitaxel Injection USPSolution6 mgIntravenousAccord Healthcare Inc2014-07-02Not applicableCanada
Paclitaxel Injection, USPSolution6 mgIntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PaxeneLiquid6 mgIntravenousBaker Norton Pharmaceuticals Inc.Not applicableNot applicableCanada
TaxolSolution6 mgIntravenousBristol Myers Squibb Canada1993-12-312012-07-20Canada
Teva-paclitaxel for InjectionLiquid6 mgIntravenousTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paclitaxel InjectableSolution6 mgIntravenousApotex Inc2005-02-07Not applicableCanada
PaclitaxelInjection, solution6 mg/mLIntravenousSagent Pharmaceuticals2011-09-27Not applicableUs
PaclitaxelInjection100 mg/16.7mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
PaclitaxelInjection300 mg/50mLIntravenousMylan Institutional LLC2011-09-30Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2008-09-24Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousHospira Worldwide, Inc.2002-05-08Not applicableUs
PaclitaxelInjection300 mg/50mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
PaclitaxelInjection100 mg/16.7mLIntravenousMylan Institutional LLC2011-09-30Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2008-10-23Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousFresenius Kabi USA, LLC2009-03-20Not applicableUs
PaclitaxelInjection30 mg/5mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
PaclitaxelInjection30 mg/5mLIntravenousMylan Institutional LLC2011-09-30Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2009-09-16Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousSandoz Inc2008-01-02Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousActavis Pharma, Inc.2015-01-05Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2009-11-03Not applicableUs
Paclitaxel PaclitaxelInjection, solution6 mg/mLIntravenousGland Pharma Limited2016-09-30Not applicableUs
Paclitaxel PaclitaxelInjection, solution6 mg/mLIntravenousGland Pharma Limited2016-09-30Not applicableUs
Paclitaxel PaclitaxelInjection, solution6 mg/mLIntravenousGland Pharma Limited2016-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
International Brands
NameCompany
OnxolNot Available
PaxceedNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIP88XT4IS4D
CAS number33069-62-4
WeightAverage: 853.9061
Monoisotopic: 853.330955345
Chemical FormulaC47H51NO14
InChI KeyRCINICONZNJXQF-MZXODVADSA-N
InChI
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@]12[[email protected]](OC(=O)C3=CC=CC=C3)[C@]3(O)C[[email protected]](OC(=O)[[email protected]](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[[email protected]]1OC[C@@]21OC(C)=O)C3(C)C
Pharmacology
IndicationUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Structured Indications
PharmacodynamicsPaclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Mechanism of actionPaclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
TargetKindPharmacological actionActionsOrganismUniProt ID
Apoptosis regulator Bcl-2Proteinyes
inhibitor
HumanP10415 details
Tubulin beta-1 chainProteinyes
inhibitor
HumanQ9H4B7 details
Nuclear receptor subfamily 1 group I member 2Proteinunknown
inducer
HumanO75469 details
Microtubule-associated protein 4ProteinyesNot AvailableHumanP27816 details
Microtubule-associated protein 2ProteinyesNot AvailableHumanP11137 details
Microtubule-associated protein tauProteinyesNot AvailableHumanP10636 details
Related Articles
AbsorptionWhen a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng•h/mL.
Volume of distribution
  • 227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]
Protein binding89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.
Metabolism

Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’-p-dihydroxypaclitaxel, by CYP3A4.

SubstrateEnzymesProduct
Paclitaxel
Not Available
3'-p-hydroxypaclitaxelDetails
Paclitaxel
Not Available
6a-hydrox-ypaclitaxelDetails
Paclitaxel
Not Available
6a, 3'-p-dihydroxypaclitaxelDetails
Route of eliminationIn 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.
Half lifeWhen a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.
Clearance
  • 21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]
  • 23.8 L/h/m2 [Dose 175 mg/m2, infusion duration 24 h]
  • 7 L/h/m2 [Dose 135 mg/m2, infusion duration 3 h]
  • 12.2 L/h/m2 [Dose 175 mg/m2, infusion duration 3 h]
ToxicityRat (ipr) LD50=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Paclitaxel Action PathwayDrug actionSMP00434
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 7-Hydroxystaurosporine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneThe serum concentration of Paclitaxel can be increased when it is combined with Abiraterone.Approved
ABT-263The risk or severity of adverse effects can be increased when Paclitaxel is combined with ABT-263.Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Paclitaxel.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Paclitaxel.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Paclitaxel.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aclarubicin.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paclitaxel.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Paclitaxel can be increased when it is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alemtuzumab.Approved, Investigational
AlfentanilThe serum concentration of Paclitaxel can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Paclitaxel.Approved, Investigational
AlitretinoinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alpha-Difluoromethylornithine.Experimental
ALT-110The risk or severity of adverse effects can be increased when Paclitaxel is combined with ALT-110.Investigational
AltretamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Altretamine.Approved
AmantadineThe serum concentration of Paclitaxel can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Paclitaxel.Approved, Investigational
Amg 386The risk or severity of adverse effects can be increased when Paclitaxel is combined with Amg 386.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Paclitaxel.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Paclitaxel.Approved
AminocamptothecinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminocamptothecin.Investigational
AminoglutethimideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Paclitaxel can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe metabolism of Paclitaxel can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Paclitaxel.Approved
AmlodipineThe serum concentration of Paclitaxel can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Paclitaxel.Approved, Illicit
AmonafideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Paclitaxel.Approved, Investigational
AmprenavirThe serum concentration of Paclitaxel can be decreased when it is combined with Amprenavir.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Paclitaxel.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anecortave.Investigational
annamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with annamycin.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Paclitaxel.Investigational
AP 12009The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Apaziquone.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Paclitaxel.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Paclitaxel.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Paclitaxel.Approved
AprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Paclitaxel.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arsenic trioxide.Approved, Investigational
ASA404The risk or severity of adverse effects can be increased when Paclitaxel is combined with ASA404.Investigational
AsparaginaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.Approved
AstemizoleThe serum concentration of Paclitaxel can be increased when it is combined with Astemizole.Approved, Withdrawn
AT-101The risk or severity of adverse effects can be increased when Paclitaxel is combined with AT-101.Investigational
AtazanavirThe serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Paclitaxel can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Paclitaxel.Approved
AtomoxetineThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Paclitaxel can be increased when it is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azathioprine.Approved
AZD2171The risk or severity of adverse effects can be increased when Paclitaxel is combined with AZD2171.Investigational
Azd4547The risk or severity of adverse effects can be increased when Paclitaxel is combined with Azd4547.Investigational
Azelaic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azelaic Acid.Approved
AzelastineThe serum concentration of Paclitaxel can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Paclitaxel.Approved
AzithromycinThe serum concentration of Paclitaxel can be increased when it is combined with Azithromycin.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Paclitaxel.Experimental
BarbitalBarbital may increase the hypotensive activities of Paclitaxel.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Paclitaxel.Approved
BatimastatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Paclitaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Belotecan.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Paclitaxel.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Paclitaxel.Approved
BenzocaineThe serum concentration of Paclitaxel can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Paclitaxel can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Paclitaxel.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bexarotene.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.Approved, Investigational
Bgj398The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bgj398.Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bicalutamide.Approved
BiperidenThe serum concentration of Paclitaxel can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Paclitaxel.Approved
BizelesinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Blinatumomab.Approved
Bmn 673The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bmn 673.Investigational
BoceprevirThe metabolism of Paclitaxel can be decreased when combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paclitaxel.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Paclitaxel.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paclitaxel.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Paclitaxel.Approved, Investigational
BroxuridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Paclitaxel is combined with BSI-201.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paclitaxel.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paclitaxel.Approved, Investigational
BuprenorphineThe serum concentration of Paclitaxel can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Paclitaxel can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Busulfan.Approved, Investigational
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Buthionine Sulfoximine.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabozantinib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Paclitaxel.Approved
CaiThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cai.Investigational
CalcipotriolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Camptothecin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Paclitaxel.Approved
CandesartanThe serum concentration of Paclitaxel can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Paclitaxel can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Paclitaxel can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Paclitaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Paclitaxel.Approved
CarboplatinCarboplatin may increase the myelosuppressive activities of Paclitaxel.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmustine.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Paclitaxel.Approved
CarvedilolThe serum concentration of Paclitaxel can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Paclitaxel can be increased when it is combined with Caspofungin.Approved
CatumaxomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Catumaxomab.Investigational
CB1954The risk or severity of adverse effects can be increased when Paclitaxel is combined with CB1954.Experimental
CDX-110The risk or severity of adverse effects can be increased when Paclitaxel is combined with CDX-110.Investigational
CediranibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cediranib.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Paclitaxel can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paclitaxel.Withdrawn
CetuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorambucil.Approved
ChloroquineThe serum concentration of Paclitaxel can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Paclitaxel.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
ChlorpropamideThe serum concentration of Paclitaxel can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Paclitaxel can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Paclitaxel.Approved
CholecalciferolThe metabolism of Paclitaxel can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Paclitaxel can be increased when it is combined with Cholesterol.Experimental
Cholic AcidPaclitaxel may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Paclitaxel can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Paclitaxel.Approved
CimetidineThe serum concentration of Paclitaxel can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Paclitaxel.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Paclitaxel.Approved
CladribineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Paclitaxel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Paclitaxel can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Paclitaxel.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Paclitaxel.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Paclitaxel can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Paclitaxel.Approved, Investigational
ClomipramineThe serum concentration of Paclitaxel can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Paclitaxel.Approved
ClopidogrelThe metabolism of Paclitaxel can be decreased when combined with Clopidogrel.Approved, Nutraceutical
clorarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with clorarabine.Investigational
ClotrimazoleThe metabolism of Paclitaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.Approved
CobicistatThe metabolism of Paclitaxel can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Paclitaxel.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paclitaxel.Approved
ColforsinThe serum concentration of Paclitaxel can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paclitaxel.Approved
CordycepinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cordycepin.Investigational
CrenolanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Crenolanib.Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
CyclosporineThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel.Approved
DabrafenibThe serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Paclitaxel can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Paclitaxel.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Daratumumab.Approved
DarunavirThe metabolism of Paclitaxel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Paclitaxel.Approved
DecitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Paclitaxel can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Deoxyspergualin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paclitaxel.Approved
DesipramineThe serum concentration of Paclitaxel can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Paclitaxel.Approved
DesloratadineThe serum concentration of Paclitaxel can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paclitaxel.Approved, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Paclitaxel can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Paclitaxel.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Paclitaxel can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Paclitaxel.Approved
DienogestThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dienogest.Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Paclitaxel.Approved
DihydroergotamineThe metabolism of Paclitaxel can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Paclitaxel.Illicit
DiindolylmethaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diindolylmethane.Investigational
DiltiazemThe metabolism of Paclitaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Paclitaxel.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Paclitaxel.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Paclitaxel can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Paclitaxel can be increased when it is combined with Doxepin.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Paclitaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Paclitaxel can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Paclitaxel can be decreased when combined with Dronedarone.Approved
DuloxetinePaclitaxel may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcabetThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paclitaxel.Approved
efaproxiralThe risk or severity of adverse effects can be increased when Paclitaxel is combined with efaproxiral.Investigational
EfavirenzThe serum concentration of Paclitaxel can be decreased when it is combined with Efavirenz.Approved, Investigational
EflornithineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eflornithine.Approved, Withdrawn
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Paclitaxel.Approved
EG009The risk or severity of adverse effects can be increased when Paclitaxel is combined with EG009.Investigational
ElbasvirThe serum concentration of Paclitaxel can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Paclitaxel.Approved, Investigational
ElsamitrucinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Elsamitrucin.Investigational
EltrombopagThe serum concentration of Paclitaxel can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Paclitaxel.Approved
EnalaprilThe serum concentration of Paclitaxel can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel.Approved
EndostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enoxacin.Approved
EnrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Paclitaxel.Approved, Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Paclitaxel.Approved
EpofolateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epofolate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Paclitaxel.Approved
Epothilone BThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epothilone B.Experimental, Investigational
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Paclitaxel.Approved
ErgonovineThe serum concentration of Paclitaxel can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Paclitaxel can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Paclitaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Paclitaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Paclitaxel.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Paclitaxel.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Estramustine.Approved
EstriolThe serum concentration of Paclitaxel can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Paclitaxel can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paclitaxel.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etanidazole.Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paclitaxel.Approved
Ethiodized oilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoposide.Approved
EtravirineThe serum concentration of Paclitaxel can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.Approved
ExatecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Paclitaxel is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Paclitaxel.Approved
FelodipineThe serum concentration of Paclitaxel can be increased when it is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel.Approved
FenretinideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fenretinide.Investigational
FentanylThe serum concentration of Paclitaxel can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Paclitaxel.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Paclitaxel.Approved
FiacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fiacitabine.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Paclitaxel.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Paclitaxel.Approved
FingolimodPaclitaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlavopiridolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flavopiridol.Experimental, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin.Approved
FloxuridineThe metabolism of Paclitaxel can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Paclitaxel can be decreased when combined with Fluconazole.Approved
FludarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flumequine.Withdrawn
FluorouracilThe metabolism of Paclitaxel can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Paclitaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Paclitaxel can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Paclitaxel can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Paclitaxel can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flutamide.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Paclitaxel.Approved
FluvastatinThe metabolism of Paclitaxel can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Paclitaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Paclitaxel.Approved
FosphenytoinThe metabolism of Paclitaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fotemustine.Experimental
FulvestrantThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Paclitaxel.Approved, Vet Approved
Fusidic AcidThe serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Paclitaxel is combined with G17DT.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Geldanamycin.Experimental
GemcitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine.Approved
GemfibrozilThe metabolism of Paclitaxel can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GenisteinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Paclitaxel is combined with GI-5005.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Paclitaxel can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Paclitaxel can be increased when it is combined with Glycerol.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.Approved
Gramicidin DThe serum concentration of Paclitaxel can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Paclitaxel.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paclitaxel.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gusperimus.Investigational
HadacidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.Approved, Vet Approved
HexestrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hexestrol.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Paclitaxel.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Paclitaxel.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Paclitaxel.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Paclitaxel.Approved
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyurea.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ibrutinib.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Paclitaxel.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Paclitaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ifosfamide.Approved
Il 4The risk or severity of adverse effects can be increased when Paclitaxel is combined with Il 4.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Paclitaxel.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Paclitaxel.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Paclitaxel.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imiquimod.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Paclitaxel.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Paclitaxel.Approved
IndinavirThe metabolism of Paclitaxel can be decreased when combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Indirubin.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Paclitaxel.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Paclitaxel.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Paclitaxel is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Paclitaxel is combined with INGN 225.Investigational
Interferon beta-1aThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1b.Approved
IobenguaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Iobenguane.Approved
IpilimumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ipilimumab.Approved
IrbesartanThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Irofulven.Investigational
IsavuconazoniumThe metabolism of Paclitaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paclitaxel.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paclitaxel.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Paclitaxel.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Paclitaxel.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Paclitaxel.Approved, Withdrawn
IsradipineThe metabolism of Paclitaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Paclitaxel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixazomib.Approved
KetamineThe serum concentration of Paclitaxel can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Paclitaxel.Approved
KetoconazoleThe metabolism of Paclitaxel can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Paclitaxel is combined with KOS-1584.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with L-alanosine.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Paclitaxel.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Paclitaxel.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Paclitaxel.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Paclitaxel.Approved, Investigational
LanreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Paclitaxel.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paclitaxel.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.Approved
LenvatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Paclitaxel.Approved, Investigational
LetrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Paclitaxel.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Paclitaxel.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paclitaxel.Approved
LevodopaPaclitaxel may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Paclitaxel.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Paclitaxel.Approved, Investigational
LevothyroxineThe serum concentration of Paclitaxel can be decreased when it is combined with Levothyroxine.Approved
LiarozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Liarozole.Investigational
LidocaineThe serum concentration of Paclitaxel can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Paclitaxel.Approved
LiothyronineThe serum concentration of Paclitaxel can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Paclitaxel can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Paclitaxel can be increased when it is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Paclitaxel.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Paclitaxel can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Paclitaxel.Approved
LopinavirThe metabolism of Paclitaxel can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Paclitaxel can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.Approved
LovastatinThe metabolism of Paclitaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Paclitaxel can be increased when it is combined with Lumacaftor.Approved
Ly2801653The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ly2801653.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lycopene.Approved
MafosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mafosfamide.Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Paclitaxel.Approved, Investigational
MaprotilineThe serum concentration of Paclitaxel can be increased when it is combined with Maprotiline.Approved
MasitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masitinib.Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masoprocol.Approved
MaxacalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Maxacalcitol.Approved
MDX-1106The risk or severity of adverse effects can be increased when Paclitaxel is combined with MDX-1106.Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Paclitaxel.Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Paclitaxel can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.Approved
MeprobamateThe serum concentration of Paclitaxel can be increased when it is combined with Meprobamate.Approved, Illicit
MequinolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mercaptopurine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.Withdrawn
MethadoneThe serum concentration of Paclitaxel can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Paclitaxel.Approved
MethohexitalMethohexital may increase the hypotensive activities of Paclitaxel.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Paclitaxel.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyl aminolevulinate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Paclitaxel.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Paclitaxel.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyltestosterone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Paclitaxel.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Paclitaxel.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paclitaxel.Approved, Investigational
MGI-114The risk or severity of adverse effects can be increased when Paclitaxel is combined with MGI-114.Investigational
MibefradilThe serum concentration of Paclitaxel can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Midostaurin.Investigational
MifepristoneThe serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Paclitaxel.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Paclitaxel.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Misonidazole.Investigational
MitoguazoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Paclitaxel is combined with MLN576.Investigational
ModafinilThe serum concentration of Paclitaxel can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Paclitaxel.Approved
MolgramostimThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Molgramostim.Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Paclitaxel.Approved, Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Paclitaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Paclitaxel.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paclitaxel.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Paclitaxel.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Paclitaxel.Approved
NafcillinThe serum concentration of Paclitaxel can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paclitaxel.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
NaltrexoneThe serum concentration of Paclitaxel can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NamitecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Namitecan.Investigational
NaringeninThe serum concentration of Paclitaxel can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.Approved, Investigational
NavitoclaxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Navitoclax.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Paclitaxel.Approved, Investigational
NecitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Paclitaxel.Approved
NefazodoneThe metabolism of Paclitaxel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Paclitaxel can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Paclitaxel can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Paclitaxel.Approved, Investigational
NetupitantThe serum concentration of Paclitaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Paclitaxel can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Paclitaxel can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Paclitaxel.Approved
NifedipineThe serum concentration of Paclitaxel can be decreased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilutamide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Paclitaxel.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.Approved
NimustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nimustine.Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Paclitaxel.Approved
NisoldipineThe serum concentration of Paclitaxel can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Paclitaxel can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Paclitaxel.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Paclitaxel.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Paclitaxel.Approved
NivolumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nivolumab.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Paclitaxel.Approved
Nk012The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nk012.Investigational
nocodazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nolatrexed.Investigational
NorethisteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Paclitaxel.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.Approved
OctreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Paclitaxel.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Paclitaxel.Approved, Investigational
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Omacetaxine mepesuccinate.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Paclitaxel.Approved
OmeprazoleThe serum concentration of Paclitaxel can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Paclitaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Paclitaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paclitaxel.Approved
P-NitrophenolThe serum concentration of Paclitaxel can be increased when it is combined with P-Nitrophenol.Experimental
PalbociclibThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Palifosfamide.Investigational
Palmitic AcidThe serum concentration of Paclitaxel can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Paclitaxel can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.Approved
ParoxetineThe serum concentration of Paclitaxel can be increased when it is combined with Paroxetine.Approved, Investigational
PARP inhibitorThe risk or severity of adverse effects can be increased when Paclitaxel is combined with PARP inhibitor.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Paclitaxel.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Penclomedine.Investigational
PentobarbitalThe metabolism of Paclitaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Paclitaxel can be increased when it is combined with Perindopril.Approved
PertuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pertuzumab.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Paclitaxel can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phentolamine.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenylacetic acid.Approved
PhenytoinThe metabolism of Paclitaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.Approved, Investigational
PimozideThe serum concentration of Paclitaxel can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Paclitaxel.Approved
PioglitazoneThe metabolism of Paclitaxel can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipamperone.Approved
PipobromanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paclitaxel.Approved
PixantroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Paclitaxel can be decreased when it is combined with Platelet Activating Factor.Experimental
PlevitrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Plicamycin.Approved, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podophyllin.Approved
polyacrylic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with polyacrylic acid.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ponatinib.Approved
PorfimerThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Porfimer.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with porfiromycin.Investigational
PosaconazoleThe metabolism of Paclitaxel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Paclitaxel.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Paclitaxel can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Paclitaxel can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Procarbazine.Approved
ProgesteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Paclitaxel can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Paclitaxel can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Paclitaxel.Approved, Investigational
ProtriptylineThe serum concentration of Paclitaxel can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paclitaxel.Approved
Purine RibosideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Purine Riboside.Experimental
PuromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pyrazoloacridine.Investigational
PyrimethamineThe metabolism of Paclitaxel can be decreased when combined with Pyrimethamine.Approved, Vet Approved
Qlt091001The risk or severity of adverse effects can be increased when Paclitaxel is combined with Qlt091001.Investigational
QuercetinThe serum concentration of Paclitaxel can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Paclitaxel.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Paclitaxel.Approved, Investigational
QuinidineThe serum concentration of Paclitaxel can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Paclitaxel.Approved
RabeprazoleThe metabolism of Paclitaxel can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Paclitaxel.Approved
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Paclitaxel.Approved
RamucirumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranibizumab.Approved
RanitidineThe serum concentration of Paclitaxel can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paclitaxel.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranpirnase.Investigational
RasagilineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Paclitaxel can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Remifentanil.Approved
ReserpineThe serum concentration of Paclitaxel can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rhodamine 6G.Experimental
RifabutinThe metabolism of Paclitaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Paclitaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Paclitaxel can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paclitaxel.Approved, Investigational
RilpivirineThe serum concentration of Paclitaxel can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Paclitaxel.Approved
RisperidonePaclitaxel may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Paclitaxel can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Paclitaxel.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Paclitaxel.Approved
RolapitantThe serum concentration of Paclitaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Romidepsin.Approved, Investigational
RomiplostimThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Romiplostim.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropivacaine.Approved
RoquinimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Roquinimex.Investigational
RosiglitazoneThe metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rotigotine.Approved
RubitecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rucaparib.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sacubitril.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Paclitaxel.Approved, Vet Approved
SalirasibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Salirasib.Investigational
SaquinavirThe metabolism of Paclitaxel can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Paclitaxel.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel.Approved
ScopolamineThe serum concentration of Paclitaxel can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Paclitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Paclitaxel can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Paclitaxel.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Semaxanib.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seocalcitol.Experimental
SertralineThe serum concentration of Paclitaxel can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Paclitaxel can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.Approved
SiltuximabThe serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Paclitaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Paclitaxel can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.Approved
SirolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Paclitaxel.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sodium Nitrite.Approved
Sodium phenylbutyrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sodium phenylbutyrate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Paclitaxel.Approved
SonidegibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonidegib.Approved, Investigational
SonifilanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonifilan.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Paclitaxel.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfloxacin.Approved
Sparfosic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparsomycin.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Paclitaxel.Experimental
SpironolactoneThe serum concentration of Paclitaxel can be increased when it is combined with Spironolactone.Approved
squalamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with squalamine.Investigational
SRP 299The risk or severity of adverse effects can be increased when Paclitaxel is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Paclitaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Paclitaxel can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Paclitaxel can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptokinase.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Paclitaxel can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Paclitaxel can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulindac.Approved
SumatriptanThe serum concentration of Paclitaxel can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Suramin.Approved
SwainsonineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Swainsonine.Experimental
TacrineThe serum concentration of Paclitaxel can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.Approved, Investigational
TacrolimusThe serum concentration of Paclitaxel can be decreased when it is combined with Tacrolimus.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Talaporfin.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Paclitaxel.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Paclitaxel.Approved
TegafurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tegafur.Approved
TelaprevirThe metabolism of Paclitaxel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Paclitaxel can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Paclitaxel can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temoporfin.Approved
TemozolomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Teniposide.Approved
TerazosinThe serum concentration of Paclitaxel can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Paclitaxel can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Paclitaxel can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Testolactone.Approved
TestosteroneThe serum concentration of Paclitaxel can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tetrathiomolybdate.Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tezacitabine.Investigational
TG4010The risk or severity of adverse effects can be increased when Paclitaxel is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thioridazine.Approved
ThiotepaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thymalfasin.Approved, Investigational
TiboloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Paclitaxel.Approved
TiclopidineThe metabolism of Paclitaxel can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Paclitaxel.Approved
TioguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tioguanine.Approved
TipifarnibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tivozanib.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Paclitaxel.Approved
Tnp 470The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tnp 470.Investigational
TocilizumabThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPaclitaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Paclitaxel can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Paclitaxel.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paclitaxel.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Paclitaxel.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trametinib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Paclitaxel.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
TrastuzumabThe serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Paclitaxel can be decreased when it is combined with Trazodone.Approved, Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Paclitaxel.Approved
TrifluoperazineThe serum concentration of Paclitaxel can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Paclitaxel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Paclitaxel can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Paclitaxel can be increased when it is combined with Trimipramine.Approved
TriptorelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trofosfamide.Investigational
TroleandomycinThe serum concentration of Paclitaxel can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trovafloxacin.Approved, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Troxacitabine.Investigational
TTNPBThe risk or severity of adverse effects can be increased when Paclitaxel is combined with TTNPB.Experimental
TubercidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ubenimex.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Paclitaxel.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Paclitaxel.Approved
Uracil mustardThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vadimezan.Investigational
Val 083The risk or severity of adverse effects can be increased when Paclitaxel is combined with Val 083.Investigational
Valproic AcidThe metabolism of Paclitaxel can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Valrubicin.Approved
ValsartanThe metabolism of Paclitaxel can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vapreotide.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Paclitaxel.Approved
VeliparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Paclitaxel.Approved
VenlafaxineThe metabolism of Paclitaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Paclitaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vindesine.Approved
VinflunineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinflunine.Approved
VinorelbinePaclitaxel may increase the neurotoxic activities of Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Paclitaxel can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.Approved, Investigational
ZafirlukastThe metabolism of Paclitaxel can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Paclitaxel.Approved
ZimelidineThe serum concentration of Paclitaxel can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Paclitaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Zorubicin.Experimental
Food Interactions
  • Avoid echinacea.
  • Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel.
References
Synthesis Reference

Hendricus B. A. de Bont, Ruben G. G. Leenders, Johan W. Scheeren, Hidde J. Haisma, Dick de Vos, “Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy.” U.S. Patent US5760072, issued September, 1989.

US5760072
General References
  1. Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. [PubMed:7850785 ]
  2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. [PubMed:5553076 ]
  3. Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. [PubMed:688258 ]
  4. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [PubMed:7603142 ]
  5. Authors unspecified: ABI 007. Drugs R D. 2004;5(3):155-9. [PubMed:15139776 ]
  6. Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. doi: 10.1007/978-1-60761-609-2_26. [PubMed:20217610 ]
External Links
ATC CodesL01CD01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (220 KB)
MSDSDownload (74 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.914
Blood Brain Barrier-0.9748
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8345
P-glycoprotein inhibitor IInhibitor0.5509
P-glycoprotein inhibitor IINon-inhibitor0.7309
Renal organic cation transporterNon-inhibitor0.9349
CYP450 2C9 substrateNon-substrate0.837
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7278
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8937
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9158
BiodegradationNot ready biodegradable0.9491
Rat acute toxicity2.4391 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9978
hERG inhibition (predictor II)Non-inhibitor0.7982
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for suspensionIntravenous5 mg/ml
Injection, powder, lyophilized, for suspensionIntravenous100 mg/20mL
Powder, for suspensionIntravenous100 mg
InjectionIntravenous100 mg/16.7mL
InjectionIntravenous30 mg/5mL
InjectionIntravenous300 mg/50mL
InjectionIntravenous6 mg/mL
Injection, solutionIntravenous6 mg/mL
Injection, solution, concentrateIntravenous6 mg/mL
SolutionIntravenous6 mg
LiquidIntravenous6 mg
Prices
Unit descriptionCostUnit
Abraxane 100 mg vial1119.6USD vial
Taxol 30 mg/5 ml vial35.06USD ml
Onxol 30 mg/5 ml vial34.54USD ml
Onxol 300 mg/50 ml vial34.54USD ml
Paclitaxel 300 mg/50 ml vial5.31USD ml
Paclitaxel 100 mg/16.7 ml vial4.45USD ml
Paclitaxel 30 mg/5 ml vial3.54USD ml
Paclitaxel 150 mg/25 ml vial3.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2086874 No1998-09-012013-01-07Canada
CA2155947 No2007-08-212014-02-22Canada
US5439686 No1993-02-222013-02-22Us
US5498421 No1993-03-122013-03-12Us
US7758891 No2006-02-212026-02-21Us
US7820788 No2004-10-272024-10-27Us
US7923536 No2003-12-092023-12-09Us
US8034375 No2006-08-132026-08-13Us
US8138229 No2003-12-092023-12-09Us
US8268348 No2006-02-212026-02-21Us
US8314156 No2003-12-092023-12-09Us
US8853260 No2000-10-102020-10-10Us
US9101543 No2006-02-212026-02-21Us
USRE41884 No1996-08-142016-08-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point216-217 °CFDA label
water solubilityInsolubleFDA label
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00556 mg/mLALOGPS
logP3.2ALOGPS
logP3.54ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)10.36ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area221.29 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity218.29 m3·mol-1ChemAxon
Polarizability87.17 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • N-benzylbenzamide
  • Beta amino acid or derivatives
  • Phenylpropylamine
  • Benzoate ester
  • Benzylether
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Alpha-acyloxy ketone
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Carboxamide group
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8. [PubMed:16741658 ]
  2. Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006 Aug;387(8):1081-6. [PubMed:16895478 ]
  3. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24. [PubMed:17062688 ]
  4. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N: Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology. 2006;73(4):205-12. [PubMed:17119350 ]
  5. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007 May 1;120(9):1891-8. [PubMed:17230521 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY: Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer. 2009 Jul 3;8:43. doi: 10.1186/1476-4598-8-43. [PubMed:19575780 ]
  4. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci. 1992 Apr;13(4):134-6. [PubMed:1350385 ]
  5. Kovacs P, Csaba G, Pallinger E, Czaker R: Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena. Cell Biol Int. 2007 Jul;31(7):724-32. Epub 2007 Jan 14. [PubMed:17314054 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [PubMed:18839173 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name:
MAP4
Uniprot ID:
P27816
Molecular Weight:
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name:
MAP2
Uniprot ID:
P11137
Molecular Weight:
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the ce...
Gene Name:
MAPT
Uniprot ID:
P10636
Molecular Weight:
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  4. Jang SH, Wientjes MG, Au JL: Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42. [PubMed:11504826 ]
  5. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  7. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53. [PubMed:14499271 ]
  8. Walle UK, Walle T: Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998 Apr;26(4):343-6. [PubMed:9531522 ]
  9. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  10. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  11. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674 ]
  12. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. [PubMed:15211078 ]
  13. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG: Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010 Feb 10;627(1-3):92-8. doi: 10.1016/j.ejphar.2009.11.008. Epub 2009 Nov 10. [PubMed:19903471 ]
  14. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050 ]
  15. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  16. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
  2. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD, Chen ZS: Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009 Mar 15;77(6):993-1001. doi: 10.1016/j.bcp.2008.12.005. Epub 2008 Dec 25. [PubMed:19150344 ]
  3. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8. [PubMed:16210916 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42